BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol 2014; 20(22): 6995-7004 [PMID: 24944494 DOI: 10.3748/wjg.v20.i22.6995] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Qian J, Oppermann E, Tran A, Imlau U, Qian K, Vogl TJ. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model. World J Gastroenterol 2016;22:5042-9. [PMID: 27275096 DOI: 10.3748/wjg.v22.i21.5042] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Labeur TA, Takkenberg RB, Klümpen HJ, van Delden OM. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2019;42:230-8. [PMID: 30488302 DOI: 10.1007/s00270-018-2118-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Chen CS, Li FK, Guo CY, Xiao JC, Hu HT, Cheng HT, Zheng L, Zong DW, Ma JL, Jiang L, Li HL. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 2016;7:7241-52. [PMID: 26769845 DOI: 10.18632/oncotarget.6892] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
4 Niu JX, Meng XK, Ren JJ. Studied microRNA gene expression in human hepatocellular carcinoma by microRNA microarray techniques. World J Gastroenterol 2015;21:12605-11. [PMID: 26640336 DOI: 10.3748/wjg.v21.i44.12605] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Xu XF, Xing H, Han J, Li ZL, Lau WY, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Li C, Wu MC, Shen F, Yang T. Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China. JAMA Surg. 2019;154:209-217. [PMID: 30422241 DOI: 10.1001/jamasurg.2018.4334] [Cited by in Crossref: 85] [Cited by in F6Publishing: 69] [Article Influence: 42.5] [Reference Citation Analysis]
7 Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, Imajo K, Aoki Y, Saito H, Kunieda E. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122:2041-2049. [PMID: 27062278 DOI: 10.1002/cncr.30008] [Cited by in Crossref: 96] [Cited by in F6Publishing: 74] [Article Influence: 19.2] [Reference Citation Analysis]
8 Park S, Kim TS, Kang SH, Kim HB, Park JW, Kim SK. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization. Medicine (Baltimore) 2018;97:e12311. [PMID: 30212970 DOI: 10.1097/MD.0000000000012311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
9 Yang H, Wang J, Li Z, Yang Y, Yang L, Zhang Y, Shi Y, Cao Y, Zhou J, Wang Z, Chen Q. Risk Factors and Outcomes of Early Relapse After Curative Resection of Intrahepatic Cholangiocarcinoma. Front Oncol 2019;9:854. [PMID: 31555597 DOI: 10.3389/fonc.2019.00854] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Nakano MM, Yamamoto A, Nishida N, Hamuro M, Hamamoto S, Jogo A, Sohgawa E, Kageyama K, Minami T, Miki Y. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Jpn J Radiol 2019;37:543-8. [DOI: 10.1007/s11604-019-00840-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Miki I, Murata S, Uchiyama F, Yasui D, Ueda T, Sugihara F, Saito H, Yamaguchi H, Murakami R, Kawamoto C, Uchida E, Kumita SI. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy. World J Gastroenterol 2017;23:6437-47. [PMID: 29085193 DOI: 10.3748/wjg.v23.i35.6437] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lee S, Kim H, Ji Y, Cho B, Kim SS, Jung J, Kwak J, Park JH, Lee SW, Kim JH, Yoon SM. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration. Sci Rep 2018;8:16224. [PMID: 30385839 DOI: 10.1038/s41598-018-34676-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Jeong SO, Kim EB, Jeong SW, Jang JY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Goo DE, Park SY. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma. Gut Liver 2017;11:409-16. [PMID: 28208001 DOI: 10.5009/gnl16001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
15 Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, Kobashi G, Ebner DK, Okada NN, Makishima H, Miyazaki M, Kamada T, Tsujii H; Liver Cancer Working Group. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer 2017;123:3955-65. [PMID: 28662297 DOI: 10.1002/cncr.30816] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
16 Douhara A, Namisaki T, Moriya K, Kitade M, Kaji K, Kawaratani H, Takeda K, Okura Y, Takaya H, Noguchi R, Nishimura N, Seki K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Saikawa S, Nakanishi K, Furukawa M, Kubo T, Yoshiji H. Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. Oncol Lett 2017;14:3028-34. [PMID: 28927051 DOI: 10.3892/ol.2017.6489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]